)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Hepion Pharmaceuticals
Hepion Pharmaceuticals (HEPA) investor relations material
Hepion Pharmaceuticals Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary13 Aug, 2026
Executive summary
Transitioned focus from drug development to medical diagnostics, licensing liver disease diagnostic assets from Cirna Diagnostics in February 2026, with upfront and milestone payments structured.
Leadership changes included new employment agreements for the Executive Chairman and CEO in May 2026, and a new COO in August 2026.
Accumulated deficit reached $248.2 million as of June 30, 2026, with no commercial revenue generated to date.
Financial highlights
Net loss for Q2 2026 was $1.25 million, compared to $1.04 million in Q2 2025; net loss for the six months ended June 30, 2026 was $2.06 million, down from $7.15 million in the prior year period.
General and administrative expenses increased by $0.2 million year-over-year for the quarter, mainly due to higher personnel costs.
Research and development expenses decreased to $0.1 million for Q2 2026, reflecting lower activity post-asset acquisition.
Cash balance as of June 30, 2026 was $1.6 million, down from $1.8 million at year-end 2025.
Working capital stood at $1.4 million at quarter-end, compared to $2.8 million at December 31, 2025.
Outlook and guidance
Management expects continued significant losses and negative cash flows, with no commercial products anticipated for several years, if at all.
Additional capital will be required to fund ongoing operations and strategic initiatives.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hepion Pharmaceuticals
- Net loss improved to $0.8M in Q1 2026, but ongoing operations depend on securing new capital.HEPA
Q1 2026 - Shareholders will vote on directors, auditor ratification, and a major equity plan increase.HEPAProxy filing
- Shareholders will vote on director elections, auditor ratification, and a major equity plan amendment.HEPAProxy filing
- Net loss narrowed to $8.3M in 2025 as operations shifted to diagnostics, but no revenue was generated.HEPAQ4 2025
- Key votes include director elections, auditor ratification, and a reverse stock split to retain Nasdaq listing.HEPAProxy Filing
- Shareholders will vote on director elections, auditor ratification, warrant issuance, and a reverse split.HEPAProxy Filing
- Key votes include director elections, auditor ratification, and a reverse stock split to retain Nasdaq listing.HEPAProxy Filing
- Shareholders are urged to approve a merger with Pharma Two B to avoid bankruptcy risk.HEPAProxy Filing
- Shareholders will vote on director elections, a reverse stock split, auditor ratification, and executive pay.HEPAProxy Filing
Next Hepion Pharmaceuticals earnings date
Q3 202620 Nov, 2026
Hepion Pharmaceuticals
Next Hepion Pharmaceuticals earnings date
Q3 202620 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Hepion Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for liver diseases, particularly non-alcoholic steatohepatitis (NASH) and liver fibrosis. The company’s lead drug candidate, based on cyclophilin inhibition technology, aims to target inflammation, fibrosis, and viral infections affecting the liver. The company is headquartered in Edison, New Jersey, and its shares are listed on the NASDAQ.